The Department of Science and Technology (DOST) and the Food and Drug Administration (FDA) on Friday denied the claims of China-based Sinopharm that the government did not act on its papers to conduct local trials of its company’s vaccine for the coronavirus diseaes 2019 (Covid-19) in the Phlippines.
“Sinopharm reached out to DOST with two proposals for collaboration: (1) the conduct of their clinical trial to be funded by the Philippines, or (2) the Philippines will recognize the approval/authorization from their country,” the DOST said in a joint statement with the Department of Health (DOH) and Food and Drug Administration (FDA) on Friday.
The DOST said it responded to the Chinese vaccine’s firm letter, emphasizing government can only fund the trials under the World Health Organization’s solidarity trial protocol. The DOST said it got no response from Sinopharm thereafter,
The agency was responding to what two representatives of MKG Universal Drug Trading Corporation, claiming to be the “sole and exclusive” Philippine distributor of the Sinopharm-developed vaccine, or that it sent a letter to Health Secretary Francisco Duque 3rd last May 2020. In the letter, Sinopharm was seeking to collaborate with the Philippine government to conduct local trials of its Covid-19 vaccines.
The MKG representatives claimed Duque never responded to their letter.
The DOH said it “categorically denies” the accusations of the representatives.
“The DOH categorically denies these baseless accusations and clarifies that the country’s participation in several clinical trials including that of Sinopharm’s was approved by the Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) as early as May, as resolved in the IATF-EID Resolution No. 39 dated 22 May 2020,” the DOH said.
Sinopharm was the firm that supplied the vaccines used to immunize members of the Presidential Security Group against Covid-19. SOVEREIGNPH